Cogent Biosciences, INC Form 4 insider transactions

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., was granted stock options valued at $38.48 per share, with 627 options awarded on July 1, 2026.

Andrew R. Robbins, President and CEO of Cogent Biosciences, transferred 160,000 shares of common stock to a family trust on May 19, 2026, for estate planning.

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., was granted stock options as part of her compensation for services.

Fairmount Funds Management LLC converted preferred stock into 7 million common shares of Cogent Biosciences, then sold all those shares for $34.66 each.

Fairmount Funds Management LLC, a 10% owner and director of Cogent Biosciences, Inc., reported the sale of 3.5 million shares of common stock for $36.40 per share under a pre-arranged plan.

Cogent Biosciences director Karen Jean Ferrante was granted 643 stock options as part of her compensation, aligning her interests with shareholders.

Cogent Biosciences' Chief Legal Officer, Evan Kearns, sold 65,000 shares of common stock for approximately $2.5 million under a pre-arranged trading plan.

John L. Green, Chief Financial Officer of Cogent Biosciences, Inc., sold 77,000 shares of common stock at a weighted average price of $38.68 per share.

Cogent Biosciences' Chief Medical Officer, Jessica Sachs, sold 82,642 shares of common stock for a weighted average price of $38.70 per share.

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, sold 90,000 shares of common stock for a weighted average price of $38.74 per share.

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, reported the acquisition of 370,000 shares of common stock and 65,000 stock options, alongside the surrender of 139,998 shares for tax withholdings.

Cogent Biosciences CEO Andrew R. Robbins acquired significant equity through RSU vesting and stock options, while also selling shares for tax obligations.

Cogent Biosciences' Chief Commercial Officer, Cole Pinnow, increased beneficial ownership through RSU vesting and new option grants, while also selling shares for tax obligations.

Cogent Biosciences' Chief Legal Officer, Evan Kearns, reported significant equity transactions including RSU awards, PSU vesting, and stock option grants.

Cogent Biosciences' Chief Medical Officer, Jessica Sachs, filed a Form 4 detailing future equity transactions including RSU vesting, tax-related share disposition, and new stock option grants effective December 17, 2025.

Cogent Biosciences' Chief Financial Officer, John L. Green, reported significant equity transactions including RSU awards, PSU vesting, and stock option grants.

Cogent Biosciences Director Karen Jean Ferrante acquired 1,642 stock options as part of her compensation, aligning her interests with shareholders.

Fairmount Funds Management LLC, a 10% owner and director of Cogent Biosciences, Inc., plans to acquire an additional 2.78 million shares of common stock for $9 per share in July 2025.

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., received 3,314 stock options as part of her compensation, electing equity in lieu of cash for her services.

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., was granted 44,700 stock options with an exercise price of $5.64, aligning her interests with shareholder value.

Christopher W. Cain, a Director at Cogent Biosciences, Inc., was granted 44,700 stock options with an exercise price of $5.64, which he holds for the benefit of Fairmount Funds Management LLC.

Matthew Ros, a Director at Cogent Biosciences, Inc., was granted 44,700 stock options with an exercise price of $5.64, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.

Cogent Biosciences Director Todd Shegog was granted 44,700 stock options with an exercise price of $5.64, aligning his interests with shareholder value.

Cogent Biosciences, Inc. Director Peter Evan Harwin was granted 44,700 stock options with an exercise price of $5.64, vesting over approximately one year.

Cogent Biosciences, Inc. Director Arlene Morris was granted 44,700 stock options with an exercise price of $5.64, vesting upon the earlier of the first anniversary of the grant date or the 2026 Annual Meeting of Stockholders.

Karen Jean Ferrante, a director at Cogent Biosciences, acquired 3,788 stock options in lieu of cash compensation on April 1, 2025.

John L. Green, CFO of Cogent Biosciences, Inc., was granted stock options to purchase 270,000 shares of common stock on January 23, 2025.

Cole Pinnow, Chief Commercial Officer of Cogent Biosciences, was granted stock options for 240,000 shares on January 23, 2025, vesting monthly over four years.

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, was granted 270,000 stock options on January 23, 2025.

Cogent Biosciences' Chief Medical Officer, Jessica Sachs, was granted 270,000 stock options on January 23, 2025, which vest over four years.